Item 1.01. Entry into a Material Definitive Agreement.
On March 6, 2019, SELLAS Life Sciences Group, Inc. (the "Company") entered into
a Warrant Exercise Agreement with a holder (the "Holder") pursuant to which the
Company issued warrants to purchase shares of the Company's common stock (the
"March 2019 Warrants"). In June 2019, the Company agreed to seek the approval of
The Nasdaq Stock Market to reduce the exercise price to $7.50 per share (subject
to adjustment for stock splits and the like) of the March 2019 Warrants. On
January 2, 2020, the Company and the Holder entered into an Amendment to Warrant
to Purchase Common Stock (the "Amendment"), which amended the March 2019
Warrants to provide for an exercise price of the March 2019 Warrants of $7.50
per share, subject to adjustment as set forth in such warrants. The form of the
Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the
description of the terms of the Amendment are qualified in their entirety by
reference to such exhibits.
Item 3.03. Material Modification to Rights of Security Holders.
The information contained above in Item 1.01 of this Current Report on Form 8-K
is hereby incorporated by reference into this Item 3.03.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibit
Number Description
10.1 Amendment to Warrant to Purchase Common Stock
© Edgar Online, source Glimpses